An approach to evaluating and comparing biomarkers for patient treatment selection

International Journal of Biostatistics

Volumn 10, Issue 1, 2014, Pages 99-121

  Janes, Holly ^a   Brown, Marshall D ^a   Huang, Ying ^a   Pepe, Margaret S ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Interaction; Predictive marker; Prescriptive marker; Randomized trial; Treatment selection marker

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; TAMOXIFEN; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST SURGERY; CALIBRATION; CANCER ADJUVANT THERAPY; COMPUTER PROGRAM; DISEASE MARKER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; FEMALE; HUMAN; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; SOFTWARE; TUMOR MARKERS, BIOLOGICAL;

EID: 84902515144     PISSN: None     EISSN: 15574679     Source Type: Journal    
DOI: 10.1515/ijb-2012-0052     Document Type: Article

References (47)

1. Simon R. Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 2008;44:2707-13.
2. Gunter L, Zhu J, Murphy S. Chapter Variable selection for optimal decision making. In: Proceedings of the 11th conference on artificial intelligence in medicine. Springer Verlag, 2007.
3. Coates AA, Miller EK, O'Toole SA, Molloy TJ, Viale G, Goldhirsch A, et al. Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG trials VIII and IX. Breast Cancer Res 2012;14:R143.
4. Busch S, Ryden L, Stal O, Jirstrom K, Landberg G. Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer. PLoS One 2012;7:e45669.
5. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al., and N. C. B. T. S. G. (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916-26.
6. Janes H, Pepe MS, Bossuyt PM, Barlow WE. Measuring the performance of markers for guiding treatment decisions. Ann Intern Med 2011;154:253-9.
7. Huang Y, Gilbert PB, Janes H. Assessing treatment-selection markers using a potential outcomes framework. Biometrics 2012;68:687-96.
8. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 2004;5:465-81.
9. Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 2004;23:2509-25.
10. Cai T, Tian L, Wong P, Wei L. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 2011;12:270-82.
11. Claggett B, Zhao L, Tian L, Castagno D, Wei LJ. Estimating subject-specific treatment differences for risk-benefit assessment with competing risk event-time data. Harvard University Biostatistics Working Paper Series, 1252011.
12. Zhao L, Tian L, Cai T, Claggett B, Wei LJ. Effectively selecting a target population for a future comparative study. Harvard University Biostatistics Working Paper Series, 2011.
13. Song X, Pepe MS. Evaluating markers for selecting a patient's treatment. Biometrics 2004;60:874-83.
14. Baker S, Kramer B. Statistics for weighing benefits and harms in a proposed genetic substudy of a randomized cancer prevention trial. J Royal Stat Soc Ser C (Appl Stat) 2005;54:941-54.
15. Vickers AJ, Kattan MW, Sargent D. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials 2007;8:14.
16. Brinkley J, Tsiatis AA, Anstrom KJ. A generalized estimator of the attributable benefit of an optimal treatment regime. Biometrics 2010;66:512-22.
17. Lu W, Zhang HH, Zeng D. Variable selection for optimal treatment decision. Stat Meth Med Res 2012;22(5):493-504.
18. Foster JC, Taylor JM, Ruberg SJ. Subgroup identification from randomized clinical trial data. Stat Med 2011;30:2867-80.
19. Gunter L, Zhu J, Murphy S. Variable selection for qualitative interactions in personalized medicine while controlling the family-wise error rate. J Biopharm Stat 2011;21:1063-78.
20. Qian M, Murphy S. Performance guarantees for individualized treatment rules. Ann Stat 2011;39:1180-210.
21. McKeague IW, Qian M. Evaluation of treatment policies via sparse functional linear regression. Stat Sin 2013.
22. Zhang B, Tsiatis AA, Laber EB, Davidian M. A robust method for estimating optimal treatment regimes. Biometrics 2012;68(4):1010-8.
23. Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford, UK: Oxford University Press, 2003.
24. Zhou X-H, McClish DK, Obuchowski NA. Statistical methods in diagnostic medicine. New York: Wiley, 2002.
25. Pepe MS, Janes H. Methods for evaluating prediction performance of biomarkers and tests. UW Biostatistics Working Paper Series 384, 2012.
26. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-717.
27. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007;9:R81.
28. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomized trial. Lancet Oncol 2010;11:55-65.
29. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 2004;351:2817-26.
30. Paik S, Tang G, Shak S, Chungyeul K, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen-receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
31. Albain KS, Barlow WE, Davdin PM, Farrar WB, Burton GV, Ketchel SJ, et al., and the Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, nodepositive breast cancer: A phase 3, open-label, randomized controlled trial. Lancet 2009;274:2055-63.
32. Janes H, Pepe MS, Huang Y. A framework for evaluating markers used to select patient treatment. Med Decis Making 2014;34(2):159-67.
33. Huang Y, Pepe M. Semiparametric methods for evaluating the covariate-specific predictiveness of continuous markers in matched case-control studies. J R Stat Soc Ser B 2010;59:437-56.
34. Huang Y, Pepe MS. Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods. Stat Med 2010;29:1391-410.
35. Huang Y, Sullivan Pepe M, Feng Z. Evaluating the predictiveness of a continuous marker. Biometrics 2007;63:1181-8.
36. Vickers AJ, Cronin AM, Begg CB. One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol 2011;11:13.
37. Kerr KF, McClelland RL, Brown ER, Lumley T. Evaluating the incremental value of new biomarkers with integrated discrimination improvement. Am J Epidemiol 2011;174:364-74.
38. Pepe M, Kerr K, Longton G, Wang Z. Testing for improvement in prediction model performance. UW Biostatistics Working Paper Series 379, 2011.
39. Seshan VE, Gonen M, Begg CB. Comparing ROC curves derived from regression models. Stat Med 2013;32(9):1483-93.
40. Demler OV, Pencina MJ, D'Agostino RB. Misuse of DeLONG test to compare AUCs for nested models. Stat Med 2012;31:2577-87.
41. Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology 2014;25(1):114-121.
42. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985;41:361-72.
43. Shuster J, van Eys J. Interaction between prognostic factors and treatment. Control Clin Trials 1983;4:209-14.
44. Lemeshow S, Hosmer DJ. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106.
45. Prentice RL, Pyke R. Logistic disease incidence models and case-control studies. Biometrika 1979;66:403-11.
46. Gu W, Pepe M. Measures to summarize and compare the predictive capacity of markers. Int J Biostat 2009;5:Article 27. Accessed at: http://dx.doi.org/10. 2202/1557-4679.1188
47. Benjamini Y, Yekuteili D. False discovery rate-adjusted multiple confidence intervals for selected parameters. J Am Stat Assoc 2005;100:71-81.